



TRW

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q80589

Masahiro OKUDA, et al.

Appln. No.: 10/811,385

Group Art Unit: 1651

Confirmation No.: 3080

Examiner: Not Yet Assigned

Filed: March 29, 2004

For: REAGENT FOR DETECTING ANTI-PHOSPHOLIPID ANTIBODY AND REAGENT
KIT USING THE SAME

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith, along with a copy of the corresponding Communication (European Search Report for corresponding European Patent Application No. EO 04 00 7158) from the European Patent Office.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/811,385


ATTNY. DOCKET NO.: Q80589

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


Joseph V. Ruch, Jr.
Registration No. 26,577

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 22, 2004

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/811,385
Confirmation Number	3080
Filing Date	March 29, 2004
First Named Inventor	Masahiro OKUDA
Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q80589

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,261,792	B1	07-17-2001	
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		JP	5180835	A	07-23-1993	SRL KK	Abstract
		WO	01/21183	A1	03/29/2001	The Liposome Co., Inc.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		JACOBSEN et al., The Evaluation of Clotting Times In The Laboratory Detection Of Lupus Anticoagulants, THROMBOSIS RESEARCH, November 15, 2001, pages 275-282, Vol. 104 - No. 4.	
		SAKAKURA et al., Coagulation Tests And Anti-Phospholipid Antibodies In Patients Positive For Lupus Anticoagulant, CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS: OFFICIAL JOURNAL OF THE INTERNATIONAL ACADEMY OF CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS, July 2000, pages 144-150, Vol. 6 - No. 3.	
		NORBIS FRANCESCA et al., Diluted Russell's Viper Venom Time And Colloidal Silica Clotting Time For The Identification Of The Phospholipid-Dependent Inhibitors Of Coagulation, THROMBOSIS RESEARCH, 1997, pages 427-431, Vol. 85 - No. 5.	
		SIBILIA JEAN, Antiphospholipid Syndrome: Why And How Should We Make The Diagnosis?, JOINT, BONE, SPINE: REVUE DU RHUMATISME, March 2003, pages 97-102, Vol. 70 - No. 2.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.